摘要: Which pivotal study offers the results to rely on when setting BP goals to reduce CV risk in your patients with type 2 diabetes?年份: 2018 收藏 引用 批量引用 报错 分享 全部来源 求助全文 Semantic Scholar 相似文献Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA...
What do the recently published SPRINT [1] and EMPAREG Outcome [2] trials have in common with the ALLHAT [3] and the HYVET [4] trials? All four demonstrated significant clinical benefits in terms of cardiovascular morbidity and mortality of either lowering blood pressure (BP) in high-risk ...
18 In addition, empagliflozin had a beneficial effect on MVO2, assessed indirectly via heart rate, BP, and the double product (also known as the rate pressure product [heart rate multiplied by systolic BP], an indirect measure of MVO2, and thus, of cardiac workload).18 Arterial stiffness ...
BP reduction the significant drug-induced difference in systolic BP could potentially have strongly contributed to the results; this effect is also compatible with the early divergence of the survival curves, thus playing a major role in the improved prognosis of empagliflozin-treated patients. Against...
BP, mmHg 136.0 ± 17.6 135.2 ± 16.8 Diastolic BP, mmHg 76.0 ± 10.0 76.9 ± 9.8 LDL-cholesterol, mmol/l 2.5 ± 1.0 2.1 ± 0.9 Albuminuria, % Normoalbuminuria 64.0 57.6 Microalbuminuria 26.1 29.7 Macroalbuminuria 9.2 11.7 Missing 0.7 1.0 CV pharmacotherapy, % Any BP lowering agent 94.3 ...
These results support the use of EMPA for lowering BP in patients with T2D and as a potential add-on treatment for rHT.Joao Pedro FerreiraDavid FitchettAnne Pernille OfstadBettina J KrausChristoph WannerIsabella ZwienerSabine LauerJyothis T George...
These results have been attributed to haemodynamic rather than metabolic effects, in part due to the osmotic/diuretic action of empagliflozin and the reduction in arterial blood pressure (BP). The present narrative review includes the results of meta-analyses of trials evaluating the effects on ...
We explored the effect of empagliflozin on CV death, heart failure hospitalization (HHF), 3-point major adverse cardiac events (3P-MACE), all-cause death, and incident/worsening nephropathy by Cox regression and BP over time by a mixed-repeated-measures-model analysis. RESULTS: 1579 (22.5%) ...